{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:36:50Z","timestamp":1788565010674,"version":"build-2803163510"},"reference-count":34,"publisher":"The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turk J Med Sci"],"DOI":"10.3906\/sag-1912-62","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T07:36:02Z","timestamp":1582616162000},"page":"433-441","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study"],"prefix":"10.55730","volume":"44","author":[{"given":"\u0130nsu","family":"YILMAZ","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"T\u00dcRK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakine","family":"BAH\u00c7EC\u0130O\u011eLU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri","family":"TUTAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130nci","family":"G\u00dcLMEZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"34691","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1.\tFlood-Page P, Swenson C, Faiferman I, Matthews J, Williams M et al. International mepolizumab study group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. American Journal of Respiratory and Critical Care Medicine 2007; 176: 1062-1071.","DOI":"10.1164\/rccm.200701-085OC"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2.\tLeckie MJ, ten Brinke A, Khan J, Diamant Z, O\u2019Connor BJ et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000; 356 (9248): 2144-2148.","DOI":"10.1016\/S0140-6736(00)03496-6"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"3.\tBel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine 2014; 371: 1189-1197.","DOI":"10.1056\/NEJMoa1403291"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4.\tPavord ID, Korn S, Howarth P, Bleecker ER, Buhl R et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5.\tOrtega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine 2014; 371: 1198-1207.","DOI":"10.1056\/NEJMoa1403290"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6.\tBousquet J, Chanez P, Lacoste JY, u2c81, Ghavanian N et al. Eosinophilic inflammation in asthma. New England Journal of Medicine 1990; 323(15): 1033-1039.","DOI":"10.1056\/NEJM199010113231505"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7.\tAmelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH et al. Severe adult-onset asthma: a distinct phenotype. Journal of Allergy and Clinical Immunology 2013; 132: 336-341.","DOI":"10.1016\/j.jaci.2013.04.052"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8.\tFajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. Journal of Allergy and Clinical Immunology 2015; 135: 299-310.","DOI":"10.1016\/j.jaci.2014.12.1871"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9.\tde Groot JC, ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. European Respiratory Journal Open Research 2015; 1: 00024-02015.","DOI":"10.1183\/23120541.00024-2015"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10.\tMoore WC, Meyers DA, Wenzel SE, Teague WG, Li H et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. American Journal of Respiratory and Critical Care Medicine 2010; 181 (4): 315-323.","DOI":"10.1164\/rccm.200906-0896OC"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11.\tYilmaz \u0130, TerI M. Asthma management: a new phenotype based approach using presence of eosinophilia and allergy. Allergy 2017; 72 (10): 1587-1589.","DOI":"10.1111\/all.13188"},{"key":"ref12","unstructured":"12.\tY\u0131lmaz \u0130, Turk M, Bahcecioglu SN. Eosinophilic asthma with nasal polyposis march: is aspirin-exacerbated respiratory disease the last station? Journal of Allergy and Clinical Immunology: In Practice 2017; 5 (6): 1808-1809."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13.\tLicari A, Brambilla I, De Filippo M, u2c7e, u2c7f et al. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Review of Respiratory Medicine 2017; 11: 855-865.","DOI":"10.1080\/17476348.2017.1381564"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14.\tMorita H, Moro K, Koyasu S. Innate lymphoid cells in allergic and non-allergic inflammation. Journal of Allergy and Clinical Immunology 2016; 138: 1253-1264.","DOI":"10.1016\/j.jaci.2016.09.011"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15.\tDrick N, Seeliger B, Welte T, Fuge J, Suhling H. Anti-IL-5 therapy in patients with severe eosinophilic asthma\u2014clinical efficacy and possible criteria for treatment response. BMC Pulmonary Medicine 2018; 18(1): 119.","DOI":"10.1186\/s12890-018-0689-2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16.\tKurosawa M, Sutoh E. Prospective open-label study of 48-week subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma. Journal of Investigational Allergology and Clinical Immunology 2019; 29(1): 40-45.","DOI":"10.18176\/jiaci.0285"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17.\tMeltzer EO, Hamilos DL. Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines. Mayo Clinic Proceedings 2011; 86 (5): 427-443.","DOI":"10.4065\/mcp.2010.0392"},{"key":"ref18","unstructured":"18.\tFokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I et al. EPOS 2012; European position paper on rhinosinusitis and nasal polyps. A summary for otorhinolaryngologists. Rhinology 2012; 50 (1): 1-12."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19.\tBachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. Journal of Allergy and Clinical Immunology 1997; 99: 837-842.","DOI":"10.1016\/S0091-6749(97)80019-X"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20.\tZhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. Journal of Allergy and Clinical Immunology 2008; 122: 961-968.","DOI":"10.1016\/j.jaci.2008.07.008"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21.\tTomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. Journal of Allergy and Clinical Immunology 2016; 137 (5): 1449-1456.","DOI":"10.1016\/j.jaci.2015.12.1324"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22.\tBachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. Journal of Allergy and Clinical Immunology 2010; 126: 962-968.","DOI":"10.1016\/j.jaci.2010.07.007"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"23.\tVan Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immuneprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. American Journal of Rhinology & Allergy 2014; 28: 192-198.","DOI":"10.2500\/ajra.2014.28.4033"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"24.\tNair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. New England Journal of Medicine 2009; 360: 985-993.","DOI":"10.1056\/NEJMoa0805435"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25.\tBachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. Journal of Allergy and Clinical Immunology 2017; 140: 1024-1031.","DOI":"10.1016\/j.jaci.2017.05.044"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26.\tGevaert P, Van Bruaene N, Cattaert T, u2c7d, u2c80 et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. Journal of Allergy and Clinical Immunology 2011; 128: 989-995.","DOI":"10.1016\/j.jaci.2011.07.056"},{"key":"ref27","unstructured":"27.\tHeffler E, Nascimento Girardi Madeira L, Ferrando M, Puggioni F, Racca F et al. Inhaled corticosteroids safety and adverse effects in patients with asthma. Journal of Allergy and Clinical Immunology: In Practice 2018; 3: 2213-2198."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28. u2c7b, u2c7c, u2c79, u2c7a, u2c78. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study. Pulmonary Pharmacology and Therapeutics 2018; 53: 1-5.","DOI":"10.1016\/j.pupt.2018.09.006"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"29. Yancey SW, Keene ON, Albers FC, Ortega H, Bates S et al. Biomarkers for severe eosinophilic asthma. Journal of Allergy and Clinical Immunology 2017; 140: 1509-1518.","DOI":"10.1016\/j.jaci.2017.10.005"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine 2016; 4: 549-556.","DOI":"10.1016\/S2213-2600(16)30031-5"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"31. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respiratory Medicine 2015; 3(11): 849-858.","DOI":"10.1016\/S2213-2600(15)00367-7"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"32. Zeiger RS, Schatz M, Li Q, Chen W, Khatry DB et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. Journal of Allergy and Clinical Immunology: In Practice 2014; 2(6): 741-750.","DOI":"10.1016\/j.jaip.2014.06.005"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"33. Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES et al. Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma. Journal of Allergy and Clinical Immunology: In Practice 2018; 6(3): 874-882.","DOI":"10.1016\/j.jaip.2017.11.026"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"34. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil\u2019s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. American Journal of Respiratory and Critical Care Medicine 2003; 167: 199-204.","DOI":"10.1164\/rccm.200208-789OC"}],"container-title":["TURKISH JOURNAL OF MEDICAL SCIENCES"],"original-title":[],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T07:22:43Z","timestamp":1655709763000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.tubitak.gov.tr\/medical\/vol50\/iss2\/21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,4,6]]}},"URL":"https:\/\/doi.org\/10.3906\/sag-1912-62","relation":{},"ISSN":["1303-6165"],"issn-type":[{"value":"1303-6165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]}}}